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To date the published data on COVID-19 in children remain very limited, and most 
reports originate from China. This study aimed to capture key data on children with 
SARS-CoV-2 infection across Europe to inform physicians and healthcare service 
planning during the ongoing pandemic. 
 
Methods 
Multicentre study involving 82 participating healthcare institutions across 
25 European countries, using a well-established research network – the Paediatric 
Tuberculosis Network European Trials Group (ptbnet) – mainly comprising Paediatric 
Infectious Diseases specialists and Paediatric Pulmonologists, over a 3·5-week period 
in April 2020, at the initial peak of the European COVID-19 pandemic. Inclusion 
criteria comprised: age ≤18 years and SARS-CoV-2 detected at any anatomical site. 
 
Findings 
A total of 582 PCR-confirmed cases were included [median age: 5·0 years (IQR: 0·5-
12·0); male to female ratio 1·15:1]. One-hundred forty-five (24·9%) had significant 
pre-existing medical conditions. The majority (n=363; 62·4%) were admitted to 
hospital. Forty-eight (8·2%) required intensive care unit (ICU) support, 25 (4·3%) 
mechanical ventilation (median duration: 7 days; range: 1-34 days), 19 (3·3%) 
inotropic support, and one (0·1%) extracorporeal membrane oxygenation. Significant 
risk factors for requiring ICU support in multivariate analyses were age <1 month, 
male gender, pre-existing medical condition, and presence of lower respiratory tract 
infection symptoms at presentation. The most frequently used drug with antiviral 
activity was hydroxychloroquine, followed by remdesivir, lopinavir/ritonavir and 
oseltamivir. Immunomodulatory medication used included corticosteroids, 
intravenous immunoglobulin, tocilizumab, anakinra and siltuximab. Four children 
died (case fatality rate: 0·69%; 95%CI: 0·20-1·82%); the remaining 578 survived 






COVID-19 is generally a mild disease in children, including infants. However, a 
small proportion develop severe disease requiring ICU support and prolonged 
ventilation, although fatal outcome is overall rare. The data also reflect the current 
uncertainties regarding specific treatment options, highlighting that additional data on 
antiviral and immunomodulatory drugs are urgently needed.   
 
Funding 







Evidence before this study 
We conducted a Medline search through the PubMed interface to identify publications 
describing clinical studies in children with COVID-19 on the 7th of May 2020. To 
make the search broad, the search terms used were: (child OR children OR pediatric 
OR paediatric) AND COVID-19; no additional limits were set. This yielded a total of 
809 papers: 332 were unrelated to children with COVID-19; 104 case reports or case 
series; 38 epidemiological reports; 66 guidelines and consensus statements; 184 
reviews, perspectives, or editorials without original data; and 53 letters. Twenty-two 
papers presented original data, but exclusively in adults. Only 10 papers reported 
clinical studies in children with COVID-19: eight papers originated from China, one 
from Spain and one from Italy. The study by Tagarro et al. was reported in letter 
format, and only included 41 children with confirmed SARS-CoV-2 infection in 
Madrid. The study from Italy by Parri et al. was also reported as a letter and included 
100 cases across several Italian hospitals. However, the study only featured a single 
patient who required mechanical ventilation, and consequently very little data on 
children with COVID-19 at the severe end of the disease spectrum.  
 
Added value of the study 
This study is the first multinational, multicentre study in children with COVID-19, 
and provides a detailed overview on SARS-CoV-2 infection in children in Europe 
during the initial peak of the pandemic, which was facilitated by a collaboration of 82 
units across 25 European countries. The study has several key findings. Firstly, the 
data show that COVID-19 is generally a mild disease in children, including infants. 
Secondly, the study found that a significant proportion of children develop severe 
disease, requiring intensive care support and prolonged ventilation. Several 
predisposing factors for requiring intensive care support were identified. Thirdly, the 
study confirms that fatal outcome is rare in children. There was considerable 
variability in the use of drugs with antiviral activity as well as immunomodulatory 
medication, reflecting current uncertainties regarding specific treatment options. 
 
Implications of all the available evidence 
This study confirms previous reports from China suggesting that the case fatality rate 
of COVID-19 in children is substantially lower than in elderly patients. However, 
some children develop severe disease and require prolonged intensive care support, 
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which should be accounted for in the planning of healthcare services and allocation of 
resources during the ongoing pandemic. Finally, the findings highlight that data on 
antiviral and immunomodulatory drugs are urgently needed from well-designed, 
randomised controlled trials in children, to enable paediatricians to make evidence-
based decision regarding treatment choices for children with severe COVID-19.  
	 10	
Introduction 
In late December 2019, the World Health Organization was notified of an unusual 
cluster of pneumonia cases in Wuhan, China. The disease, later termed coronavirus 
disease 2019 (COVID-19), spread quickly beyond the borders of China, with the first 
cases in Europe being recorded on 25 January 2020.1  
 
Subsequent investigations identified a novel betacoronavirus now designated as 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 Currently there are 
no antiviral treatment options with proven efficacy, but several randomized controlled 
trials (RCTs) are currently investigating a number of agents, including 
hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir (e.g. 
NCT04336904, NCT04328285 and NCT04280705). Other trials are focusing on 
immunomodulators, including tocilizumab and anakinra (e.g. NCT04317092 and 
NCT04330638). 
 
To date, the available data on COVID-19 in children and adolescents remain very 
limited, despite the number of confirmed COVID-19 cases now exceeding five 
million globally.3,4 Most published data originate from China, which cannot 
necessarily be extrapolated to children in Europe and elsewhere.5-12 Also, existing 
papers from China contain very few clinical data on children, and most lack details 
regarding supportive measures required by children with COVID-19. Similarly, recent 
epidemiological reports from Europe and North America contain limited clinically 
relevant information.13,14 Determining the level of support required by children is 
essential for paediatric service planning during the ongoing COVID-19 pandemic.  
 
By use of a well-established research network, predominately comprising Paediatric 
Infectious Diseases specialists and Paediatric Pulmonologists, the aim of this study 
was to rapidly capture key data on COVID-19 in children in Europe on a large scale, 
to aid physicians in Europe and in other geographical locations with service planning 




European members of the Paediatric Tuberculosis Network European Trials Group 
(ptbnet), which currently includes 304 clinicians and researchers, most of whom are 
based at tertiary/quaternary Paediatric Infectious Diseases or Paediatric Pulmonology 
units, across 128 paediatric healthcare institutions in 31 European countries,15-20 were 
invited to contribute confirmed COVID-19 cases that had been managed at or 
managed remotely by their healthcare institution (including cases admitted to other 
hospitals and cases identified during community screening). A standardized data 
collection spreadsheet was used by collaborators to record the data from their centre. 
All data were reviewed by three of the investigators (FG, BSG, and MT), and any 
inconsistencies and other data queries were clarified with the reporting 
collaborator(s). Units that did not see any cases prior to or during the study period 
were asked to report the absence of cases fulfilling the inclusion criteria at the end of 
the study period. The study was conducted over a 3·5-week period, from April 1 to 
April 24, 2020.  
 
Study definitions 
A confirmed COVID-19 case was defined as a patient in whom SARS-CoV-2 was 
detected in any clinical sample (respiratory tract, blood, stool or cerebrospinal fluid) 
by reverse transcriptase polymerase chain reaction (RT-PCR). PCR testing was 
performed as part of routine clinical care, and therefore done according to local 
testing guidelines in place at the time. The upper age-limit for inclusion was 18 years. 
Date of symptom onset was defined as the day when the first symptom or sign 
occurred, and date of diagnosis as the day when SARS-CoV-2 was first detected. 
Pyrexia was defined as a body temperature ≥38·0oC. Index case was defined as the 
most likely source case based on history; if multiple family members were affected, 
the person who displayed symptoms first was recorded. The diagnosis of upper 
respiratory tract infection (URTI) was based on clinical symptoms, encompassing any 
of the following: coryza, pharyngitis, tonsillitis, otitis media, sinusitis. Lower 
respiratory tract infection (LRTI) was based on clinical signs and auscultation 
findings. Inotropic support was defined as administration of dopamine, dobutamine, 






Non-parametric two-tailed Mann Whitney U tests were used to compare continuous 
variables, and chi-square or Fisher’s exact tests for categorical variables, as 
appropriate. The 95% confidence interval (95%CI) around the case fatality rate was 
calculated with the Wald method. Normality of data distribution was assessed with 
the Shapiro-Wilk test. The clinical end point was the need for admission to an 
intensive care unit [(ICU); either neonatal or paediatric intensive care]. Multivariable 
logistic regression analysis was performed with backward stepwise analysis exploring 
the variables significantly associated with ICU admission in univariate analysis. 
Factors associated with drug treatment were also explored. All probabilities are two-
tailed. P-values <0·05 were considered statistically significant. All analyses were 




The study was reviewed and approved by the ptbnet steering committee, and the 
human research ethics committees of the University of Bochum, Germany (19-6545-
BR), the Hospital Gregorio Marañon, Spain (CEIM HGUGM-177/20) and the city of 
Vienna, Austria (EK 20-071-VK). The study was conducted in accordance with the 
Declaration of Helsinki and its subsequent amendments. No personal or identifiable 
data were collected during the conduct of this study. 
 
Role of the funding sources 
The funders had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the manuscript. The corresponding author had full 
access to all of the data and had the final responsibility to submit for publication.  
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Results 
In total, 585 cases were reported from 77 healthcare institutions located in 21 
European countries, including Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, 
Germany, Greece, Hungary, Ireland, Italy, Lithuania, Norway, Portugal, Slovakia, 
Slovenia, Spain, Sweden, Switzerland, Turkey, and United Kingdom (Figure 1). 
Three cases did not meet the inclusion criteria (one 21-year-old; two diagnosed with 
COVID-19 based on serological testing, but PCR-negative). Participating units (n=5) 
in The Netherlands, Moldova, Ukraine, and Russia, reported not having encountered 
any cases.  
 
A total of 582 PCR-confirmed COVID-19 cases were included in the final analyses. 
The majority (n=454; 78·0%) were contributed by tertiary/quaternary healthcare 
institutions; fewer had been diagnosed in secondary (n=54; 9·3%) or primary 
healthcare (n=74; 12·7%) settings. 
 
The median age of the study population was 5·0 years (range: 3 days-18 years; 
Table 1). Age was non-normally distributed (W=0·8710; p<0·0001), with more than 
a quarter (n=170; 29·2%) of cases aged <12 months (Figure 2). The male to female 
ratio was 1·15:1. The most common source of infection was a parent, considered the 
index case in 324 (55·6%) children; in 24 (4·1%) the likely index case was a sibling. 
In the remaining 234 (40·2%) children the index case was a person outside the 
immediate family or unknown. The majority of children (n=363; 62·4%) were 
admitted to hospital; 48 (8·2%) required admission to an ICU for additional support 
(corresponding to 13·2% of children admitted to hospital).  
 
Pre-existing medical conditions and medication 
Overall 437 (75·1%) cases had no pre-existing medical conditions. The remaining 
145 (24·9%) children had significant medical conditions, most commonly chronic 
pulmonary disease (n=29, 5·0%; asthma: n=16; bronchopulmonary dysplasia: n=6), 
followed by malignancy (n=27, 4·6%; leukaemia/lymphoma: n=14; solid tumours: 
n=11), neurological conditions (n=26, 4·5%; epilepsy: n=9; cerebral palsy: n=8), 
congenital heart disease (n=25, 4·3%), chromosomal abnormalities (n=10, 1·7%; 
trisomy 21: n=8), and chronic renal disease (n=9, 1·5%). Seventeen patients had two 
or more pre-existing medical conditions. 
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Twenty-nine (5·0%) patients were receiving immunosuppressive medication at the 
time of COVID-19 diagnosis. Three (0·5%) had a previously diagnosed 
immunodeficiency, comprising common variable immunodeficiency, congenital 
neutropenia and Schimke immuno-osseous dysplasia. Twenty-five (4·3%) cases were 
receiving chemotherapy at the time of their diagnosis or had received chemotherapy 
in the preceding 6 months. Three (0·5%) had previously undergone human stem cell 
transplant. 
 
Signs and symptoms  
Pyrexia was common, observed in 379 (65·1%) cases. Approximately half had 
symptoms or signs of URTI and approximately one quarter had evidence of LRTI 
(Table 1); 128 (22·0%) had gastrointestinal symptoms. Forty (6·9%) patients with 
gastrointestinal symptoms had no respiratory symptoms; the majority of these patients 
had pyrexia (n=26; 65·0%). Ninety-two (16·0%) children were asymptomatic.   
 
Symptom onset and time of diagnosis 
The dates when SARS-CoV-2 infection was confirmed by RT-PCR in the study 
population are summarized in Figure 3. The median interval between symptom onset 
and diagnosis was 2 days (IQR: 1-4 days; range: 0-23 days); in the majority (n=391; 
67·2%) of cases the interval was ≤3 days. In eight cases SARS-CoV-2 infection was 
confirmed before any signs or symptoms were present, mainly neonates born to 
SARS-CoV-2-positive mothers and household members of known, symptomatic 
COVID-19 cases. 
 
Radiological findings and additional virological investigations 
A chest radiograph was performed in 198 (34·0%) patients. Of those, 93 (47·0%) had 
changes consistent with pneumonia. Ten (5·1%) had changes suggestive of acute 
respiratory distress syndrome (ARDS), and all these patients required mechanical 
ventilation. In 29 (5%) cases additional viruses were detected in respiratory samples, 
comprising entero-/rhinovirus (n=18), influenza virus (n=5), parainfluenza virus 
(n=3), adenovirus (n=3), respiratory syncytial virus (RSV; n=2), bocavirus (n=2), 
coronavirus NL63, coronavirus HKU1, coronavirus OC43, and human 
metapneumovirus (n=1, each); in six cases two and in one three viruses were detected 
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simultaneously. Children with dual viral infection were more likely to have URTI or 
LRTI symptoms at presentation compared to those in whom no additional viral agent 
was identified (Supplementary Appendix Table S1). Furthermore, children with 
dual viral infection were significantly more likely to require ICU admission, 
respiratory support or inotropic support.   
 
Respiratory and circulatory support  
A total of 507 (87·1%) patients did not require respiratory support at any stage. Of the 
remaining 75 (12·9%) patients who required oxygen support, 31 (5·3%) were started 
on continuous positive airway pressure (CPAP) and 25 (4·3%) on mechanical 
ventilation (including 14 that had been managed with CPAP initially). The median 
duration of mechanical ventilation was 7 days (IQR: 2·3-10·8 days; range: 1-34 days). 
One patient was started on extracorporeal membrane oxygenation. Nineteen (3·3%) 
cases required support with inotropes. 
 
Comparison of children managed with and without intensive care support  
A comparison of cases requiring ICU support and those who did not (i.e. children in 
the community and those admitted to hospital, but not needing ICU support) is shown 
in Table 1. Overall, the median age of the former group was lower (median age 4·0 
vs. 5·5 years; Figure 2), but this was not statistically significant. In univariable 
analysis, age <1 month, male gender, pre-existing medical condition, pyrexia, LRTI 
symptoms, radiological changes suggestive of pneumonia or ARDS, and dual viral 
infection were associated with ICU admission (Table 1). In multivariable analysis, 
the factors that were associated with ICU admission were: age <1 month (odds ratio 
(OR): 5·06; 95%CI: 1·72-14·87; p=0·003), male gender (OR: 2·12; 95%CI: 1·06-
4·21; p=0·033), LRTI symptoms (OR: 10·46; 95%CI: 5·16-21·23; p=<0·0001), and 
pre-existing medical condition (OR: 3·27; 95%CI: 1·67-6·42; p=0·001). 
 
Antiviral and immunomodulatory treatment 
The most commonly used drug with antiviral activity was hydroxychloroquine, used 
in 40 patients, followed by remdesivir used in 17. Lopinavir/ritonavir was used in six 
patients and oseltamivir in three (n=2 had influenza virus co-infection). Three patients 
received two drugs with antiviral activity, and one three; all four had ARDS on chest 
radiography. No patient received chloroquine, favipiravir, zanamivir or ribavirin. 
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With regard to immunomodulatory medication, 22 patients received systemic 
corticosteroids, seven intravenous immunoglobulin, four tocilizumab, three anakinra, 
and one siltuximab. Factors associated with treatment initiation of drugs with antiviral 
and/or immunomodulatory activity comprised: pre-existing malignancy, cardiac or 
respiratory disease; immunosuppressive therapy at presentation or recent 
chemotherapy; radiological findings suggestive of pneumonia or ARDS; and dual 
viral infection (Supplementary Appendix Table S2).    
 
Final outcome 
Four patients, all >10 years-of-age, had a fatal outcome [case fatality rate (CFR): 
0·69%; 95%CI: 0·20-1·82%], with death occurring at 3, 9, 11 and 17 days after 
symptom onset. Two patients had no known pre-existing medical conditions; one had 
a cardio-respiratory arrest prior to arrival in the hospital and resuscitation was 
unsuccessful; the other died while being mechanically ventilated in ICU. Another 
patient had undergone human stem cell transplant fifteen months earlier. One patient 
was managed palliatively (without intubation), due to the severity of the pre-existing 
medical conditions. The remaining 578 patients were alive when the study closed. 
Ninety-three (16·1%)	patients never developed clinical symptoms. In 460 (79·6%) 
patients all symptoms had resolved without apparent sequelae, while 25 (4·3%) were 





To our knowledge this is the first multi-national, multicentre study on paediatric 
COVID-19, and also the largest clinical study in children outside China to date. The 
inclusion of such a substantial number of cases was made possible by involving a 
large number of specialist centres across Europe via a well-established collaborative 
paediatric TB research network, allowing this study to provide one of the most 
detailed accounts of COVID-19 in children published to date. 
 
It is important to highlight that this study has primarily captured data from children 
who were seen or managed within the hospital setting, and that the majority of 
participating units were part of tertiary/quaternary healthcare institutions. 
Consequently the study population is likely to primarily represent children at the more 
severe end of the disease spectrum. Notably, a recent letter summarizing 171 PCR-
confirmed cases in Wuhan suggests that close to 20% of children with SARS-CoV-2 
infection are asymptomatic.10 At the time our study was conducted, testing capacity 
for SARS-CoV-2 in many European countries was lower than clinical demand, and 
therefore many children with symptoms consistent with COVID-19 in the community 
were not tested and consequently not diagnosed. Nevertheless, our data indicate that 
children are overall less severely affected by COVID-19 than adults, particularly 
elderly patients. Previous, large-scale data suggest that the CFR in adults >70 years is 
close to 10%,6 potentially due to immunosenescence.21 It is reassuring that our data 
show that severe COVID-19 is uncommon in young children, including infants, 
despite their immune maturation being incomplete,22,23 with only few requiring 
mechanical ventilation. Strikingly, all children who died in our cohort were older than 
10 years. 
 
A recent publication from the Centers for Disease Control and Prevention (CDC), 
summarizing epidemiological data from the United States, reported that there were a 
total of 2,572 confirmed COVID-19 cases aged <18 years as of the April 2, 2020, 
representing only 1·7% of the total number of recorded cases (n=149,760).14 A recent 
paper from the Australian Health Protection Agency also reported that children 
accounted for only 4% of the confirmed COVID-19 cases in Australia.24 
Unfortunately, in the U.S. report clinical data were only available in a small 
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proportion of patients (n=291; 11%). In concordance with our observations, fever and 
cough were the predominant clinical features at presentation (present in 56% and 54% 
of cases, respectively), with similar rates also observed in a study from Italy.25 In our 
cohort almost a quarter of patients had gastrointestinal symptoms, some of whom had 
no respiratory symptoms, and a substantial proportion of children were entirely 
asymptomatic. 
 
The CDC report also mentions three deaths, but it is unclear how many patients were 
still hospitalized by the time of publication, so it is difficult to come to firm 
conclusions regarding the CFR in U.S. children.14 Our data indicate that the CFR in 
children across Europe is below one percent. Considering that many children with 
mild disease will never have been brought to medical attention, and therefore not 
diagnosed, it is highly probable that the true CFR is substantially lower than the figure 
of 0·69% observed in our cohort. This hypothesis is further supported by an 
epidemiological study from China, in which the CFR in individuals ≤19 years was 
only 0·1% (1 death in 965 confirmed cases).6 Furthermore, our data indicate that 
sequelae related to COVID-19 are likely to be rare in children. However, after the 
closure of our study reports of a hyperinflammatory syndrome affecting children that 
is temporally, and potentially causally, associated with SARS-CoV-2 infection have 
emerged, which has subsequently been named Paediatric Inflammatory Multisystem 
Syndrome temporally associated with SARS-CoV-2 (PIMS-TS). 26,27 Further research 
will be required to characterise this emerging disease entity in detail, and determine 
the long-term outcome of affected children. 
 
Importantly, our data show that severe COVID-19 can occur both in young children 
and in adolescents, and that a significant proportion of those patients require ICU 
support, frequently including mechanical ventilation. A small, recently published 
study from Madrid also found that 4 (9·7%) out of 41 children with SARS-CoV-2 
infection required admission to ICU.2826 In our cohort, age <1 month, male gender, 
presence of LRTI symptoms at presentation, and presence of a pre-existing medical 
condition were associated with a increased likelihood of requiring ICU support.  Our 
results also show that the majority of children who are intubated due to respiratory 
failure require prolonged ventilation, often for one week or more. This contrasts with 
observations in children with RSV infection who on average only require mechanical 
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ventilation for five to seven days, 2927but is not dissimilar to observations in children 
with influenza. 3028 This has important implications for service planning, as although 
the overall demand for ICU support may be lower in children than in adults, each 
patient is likely to occupy ICU space for an extended period of time. At this time of 
intense strain on healthcare services worldwide, it is vital that adequate resources are 
allocated to paediatric services in order to sustain the provision of high-quality care 
for children.  
 
The observation that in our study children with dual viral infection (i.e. infected with 
SARS-CoV-2 and another viral agent) were more likely to require ICU support than 
those in whom SARS-CoV-2 was the only viral agent identified, may have 
implications for the winter period 2020/2021, when the incidence of other viral 
respiratory tract infections, including RSV and influenza virus infections, is bound to 
increase. This may result in a greater proportion of paediatric patients with COVID-
19 requiring ICU support than in the cohort described here, as the influenza season 
2019/2020 was already over in Europe before the study commenced (see 
https://flunewseurope.org/).   
 
Our data also reflect the uncertainties regarding drug treatment options for COVID-
19. In some countries, including Spain and Italy, national guidelines encourage the 
use of hydroxychloroquine for selected cases, as reflected in our data, while in other 
countries’ recommendations are more guarded regarding the use of antiviral agents in 
the absence of robust human data. A recently published expert consensus statement 
from the U.S. emphasized that antiviral treatment should be reserved for patients at 
the severe end of the disease spectrum, ideally within a clinical trial. 3129 Overall the 
expert panel appeared to favour the use of remdesivir over other agents, based on the 
currently available data from in vitro and animal studies, including in non-human 
primates, and recent data from compassionate use in humans. 32,3330,31 The panel 
members’ opinion was split regarding the use of lopinavir/ritonavir, given the 
disappointing results of a recently published RCT. 3432   
 
The main limitation of this study relates to the limited number of variables collected. 
In the context of the ongoing COVID-19 pandemic, to ensure high levels of 
participation and avoid diverting substantial time away from clinical frontline duties, 
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a decision was made not to collect detailed data on laboratory parameters or ICU 
interventions. A further limitation was that a variety of in-house and commercial PCR 
assays were used across different participating centres, precluding any meaningful 
assessment of diagnostic test performance. Also, the number of children receiving 
antiviral or immunomodulatory treatment was too small to draw meaningful 
conclusions regarding their effectiveness, which will be addressed by the 
aforementioned RCTs. A further limitation is that different countries were using 
different thresholds to screen for SARS-CoV-2 at the time the study was performed, 
with some recommending screening of all children admitted to hospital and/or 
conducting community screening, whilst others were using more selective testing 
strategies. Despite those limitations, this study provides the most comprehensive 
overview on COVID-19 in children and adolescents to date.     
 
In conclusion, our data, originating from a large number of specialist centres across 
Europe, show that COVID-19 is usually a mild disease in children, including infants. 
Nevertheless, a small proportion of children and adolescents develop severe disease 
and require ICU support, frequently needing prolonged ventilatory support. However, 
fatal outcome is rare overall. Our data also reflect the current uncertainties regarding 
specific treatment options, highlighting that more robust data on antiviral and 
immunomodulatory drugs are urgently needed.   
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Table 1. Baseline demographic data, pre-existing medical conditions, concomitant medication, clinical features and radiological findings at presentation 
in the entire cohort, and comparisons between patients requiring intensive care unit (ICU) support and those who did not. Figures shown are numbers 
and percentages; p-values shown are based on univariable analyses. Odds ratios refer to the likelihood of admission to ICU. 
	
 Entire cohort 
(n=582) 




p-value Odds ratio 
(95%CI) 
Age median (IQR), years 
   <2 years  
   2-5 years  
   5-10 years  
   >10 years  


















0·9 (0·9 – 1·0) 
1·4 (0·8 – 2·6) 
0·3 (0·1 – 1·4) 
1·0 (0·4 – 2·3) 
0·8 (0·4 – 1·6) 
Age <1 month  40 (6·9) 33 (6·2) 7 (14·6) 0·02 2·5 (1·0 – 6·2) 
Gender (male) 311 (53·4) 278 (52·1) 33 (68·8) 0·02 2·2 (1·0 – 3·8) 
Pre-existing medical conditions 
   Any 
   Malignancy 
   Cardiac disease 
   Respiratory disease 
   Neurological disease 
   Renal disease 
   Chromosomal abnormality 






































3·7 (2·0 – 6·8) 
2·7 (0·9 – 7·5) 
2·9 (1·0 – 8·4) 
3·1 (1·2 – 8·2) 
2·8 (1·0 – 7·9) 
3·2 (0·6 – 16·2) 
2·8 (0·5 – 13·8) 
2·4 (0·9 – 6·3) 
Immunosuppressive therapy * 29 (5·0) 26 (4·9) 3 (6·3) 0·72 1·3 (0·3 – 4·4) 
Known Immunodeficiency 3 (0·5) 3 (0·6) 0 (0) 1·00 - ** 
Chemotherapy in last 6 months  25 (4·3) 23 (4·3) 2 (4·2) 1·00 0·9 (0·2 – 4·2) 
Signs and symptoms *** 
   Asymptomatic 
   Pyrexia 
   URTI 
   LRTI 
   Gastrointestinal 






























0·2 (0·05 – 0·9) 
2·8 (1·3 – 6·2) 
0·9 (0·5 – 1·6) 
10·6 (5·4 – 20·7) 
1·6 (0·8 – 3·2) 
1·2 (0·4 – 3·4) 
Radiological findings ***** 
   Suggestive of pneumonia  














2·8 (1·3 – 5·7) 
- ** 
Dual viral infection 31 (5·3) 24 (4·5) 7 (14·6) 0·003 3·6 (1·4 – 8·9) 
*At diagnosis of COVID-19. 
** Odds ratio not calculated as one of the required values is zero. 
*** Signs and symptoms at initial presentation. 
**** Data on presence of headache only includes children ≥5 years of age in whom those data were recorded (n=255). 
***** Chest radiograph performed in n=198 only (children without ICU admission, n=156; children with ICU admission, n=42). 
Abbreviations: ARDS: acute respiratory distress syndrome, IQR: interquartile range, LRTI: lower respiratory tract infection, URTI: upper respiratory tract infection 
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Figure 1. Map showing the countries with participating units (n=81; unit locations 
indicated by blue dots), with shading indicating the number of cases contributed from 
each country. Countries highlighted in green had participating units that reported not 
having encountered any cases by study closure. Cities with more than one participating 
unit are represented by a single dot only (London n=4; Antwerp n=3; Madrid n=3; Vienna 
n=3; Barcelona n=2; Berlin n=2; Girona n=2, Manchester n=2; Rome n=2; Tallinn n=2; 























Figure 2. Violin plots showing the age distribution of patients who required intensive care 
support compared to those who did not. The solid lines represent the medians, the 























Figure 3. Violin plot illustrating the dates SARS-CoV-2 infection was confirmed by 
polymerase chain reaction in the study population, according to the country the cases 
were reported from. Countries with fewer than five cases reported are not shown. The 
shading reflects the number of cases contributed from each country. The lines represent 
the medians and the interquartile ranges. The date of the first case in each country is 
based on data reported by the European Centre for Disease Prevention and Control 
(https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html).	
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